Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CHRS - Coherus Biosciences Inc


IEX Last Trade
1.39
-0.030   -2.158%

Share volume: 593,447
Last Updated: Fri 30 Aug 2024 09:57:45 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.42
-0.03
-2.11%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
16%
Profitability 25%
Dept financing 25%
Liquidity 31%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
-9.74%
3 Months
-26.06%
6 Months
-41.10%
1 Year
-73.47%
2 Year
-87.82%
Key data
Stock price
$1.39
P/E Ratio 
-5.46
DAY RANGE
N/A - N/A
EPS 
-$0.26
52 WEEK RANGE
$1.20 - $5.33
52 WEEK CHANGE
-$0.74
MARKET CAP 
160.140 M
YIELD 
N/A
SHARES OUTSTANDING 
115.209 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
BETA 
2.59
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,199,253
AVERAGE 30 VOLUME 
$1,936,844
Company detail
CEO: Dennis Lanfear
Region: US
Website: https://www.coherus.com/
Employees: 377
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp

Recent news